Matthew Johnson
Foot & Ankle Surgery · Dallas, TXNPI 1891150777
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (59.9%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by Pylant Medical at 47.2% of the total. Reporting peaked in 2022 at $4,085 and has fallen 87.0% since, to $531 in 2025.
Across 29 payments — averaging $237.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pylant Medical$3K
- Arthrex$2K
- Musculoskeletal Transplant Foundation Inc.$921
- Integra Lifesciences Corporation$174
- Smith+Nephew$172
- Polynovo North America LLC$162
- plus $645 from 8 others
What the payments were for
- Travel & lodging$1,02915%
- Food & beverage$1,73625%
- Education$4,12760%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pylant Medical | 6 | $3,250 |
| Arthrex | 5 | $1,568 |
| Musculoskeletal Transplant Foundation Inc. | 4 | $921 |
| Integra Lifesciences Corporation | 1 | $174 |
| Smith+Nephew | 2 | $172 |
| Polynovo North America LLC | 2 | $162 |
| Paragon 28, Inc. | 1 | $145 |
| Averitas Pharma Inc. | 1 | $140 |
| Trimed, Inc. | 1 | $103 |
| Flower Orthopedics Coporation | 1 | $86 |
| Convatec Inc. | 1 | $85 |
| Kerecis Limited | 2 | $47 |
| Biocomposites Inc | 1 | $22 |
| Bioventus LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTEGRA$522
- INTEGRA DERMAL REGENERATION TEMPLATE$174
- PRIMATRIX$174
- EVOS$159
- Product Portfolio$145
- Novosorb BTM$143
- Qutenza$140
How this compares
$6,892 in reported general payments places this provider in the 65th percentile of 684 foot & ankle surgery providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Doxycycline Monohydrate | 29 | $319 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 36 | $308 |
| Ciprofloxacin Hcl | 12 | $135 |
| Methocarbamol | 27 | $127 |
| Ondansetron Hcl | 12 | $31 |
Paid to pharmacies, not to this prescriber.
Other foot & ankle surgery in Dallas
- Eugene CurryDallas$3.1M
- Paul KimDallas$928K
- John EarlyDallas$553K
- Dane WukichDallas$189K
- Charles CookDallas$92K
- Trapper LalliDallas$74K
- Veerabhadra ReddyDallas$59K
- John NoackDallas$49K
- William McGarveyKaty$3.5M
- Graham HamiltonEdinburg$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.